User profiles for "author:Mario Mandala"
mario mandalaUniversity of Perugia Verified email at unipg.it Cited by 38500 |
PD-L1 expression in cancer patients receiving anti PD-1/PD-L1 antibodies: A systematic review and meta-analysis
Background Despite the success of immunotherapy directed at inhibiting of programmed
death-1 (PD-1)/PD-ligand (L) 1 signaling, it is not established whether PD-L1 expression …
death-1 (PD-1)/PD-ligand (L) 1 signaling, it is not established whether PD-L1 expression …
PI3K-AKT-mTOR inhibition in cancer immunotherapy, redux
JS O'Donnell, D Massi, MWL Teng… - Seminars in cancer biology, 2018 - Elsevier
Cancer therapies will increasingly be utilized in combination to treat advanced malignancies
so as to increase their long-term efficacy in a greater proportion of patients. In particular …
so as to increase their long-term efficacy in a greater proportion of patients. In particular …
Targeting the PD1/PD-L1 axis in melanoma: biological rationale, clinical challenges and opportunities
A dynamic interplay exists between host and tumor, and the ability of the tumor to evade
immune recognition often determines the clinical course of the disease. Significant …
immune recognition often determines the clinical course of the disease. Significant …
[HTML][HTML] Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma
GV Long, A Hauschild, M Santinami… - … England Journal of …, 2017 - Mass Medical Soc
Background Combination therapy with the BRAF inhibitor dabrafenib plus the MEK inhibitor
trametinib improved survival in patients with advanced melanoma with BRAF V600 …
trametinib improved survival in patients with advanced melanoma with BRAF V600 …
[HTML][HTML] Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma
Background The combined inhibition of BRAF and MEK is hypothesized to improve clinical
outcomes in patients with melanoma by preventing or delaying the onset of resistance …
outcomes in patients with melanoma by preventing or delaying the onset of resistance …
[HTML][HTML] Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma
J Weber, M Mandala, M Del Vecchio… - … England Journal of …, 2017 - Mass Medical Soc
Background Nivolumab and ipilimumab are immune checkpoint inhibitors that have been
approved for the treatment of advanced melanoma. In the United States, ipilimumab has …
approved for the treatment of advanced melanoma. In the United States, ipilimumab has …
[HTML][HTML] Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma
Background Combined BRAF and MEK inhibition, as compared with BRAF inhibition alone,
delays the emergence of resistance and reduces toxic effects in patients who have …
delays the emergence of resistance and reduces toxic effects in patients who have …
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label …
Background Patients with advanced gastric or gastro-oesophageal junction cancer that
progresses on chemotherapy have poor outcomes. We compared pembrolizumab with …
progresses on chemotherapy have poor outcomes. We compared pembrolizumab with …
[HTML][HTML] Adjuvant pembrolizumab versus placebo in resected stage III melanoma
Background The programmed death 1 (PD-1) inhibitor pembrolizumab has been found to
prolong progression-free and overall survival among patients with advanced melanoma. We …
prolong progression-free and overall survival among patients with advanced melanoma. We …
Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical …
Importance Therapeutic options are needed for patients with advanced gastric cancer
whose disease has progressed after 2 or more lines of therapy. Objective To evaluate the …
whose disease has progressed after 2 or more lines of therapy. Objective To evaluate the …